---
title: "Acurx Pharmaceuticals, Inc. (ACXP.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ACXP.US.md"
symbol: "ACXP.US"
name: "Acurx Pharmaceuticals, Inc."
industry: "Biotechnology"
datetime: "2026-04-30T00:10:34.814Z"
locales:
  - [en](https://longbridge.com/en/quote/ACXP.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ACXP.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ACXP.US.md)
---

# Acurx Pharmaceuticals, Inc. (ACXP.US)

## Company Overview

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.acurxpharma.com](https://www.acurxpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.66 | 161 | - | - | - |
| PB | 1.00 | 93 | 3.77 | 2.07 | 1.67 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-13T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 67% |
| Overweight | 1 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.97 |
| Highest Target | 31.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ACXP.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ACXP.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ACXP.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ACXP.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**